<DOC>
	<DOCNO>NCT02827708</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety oral semaglutide versus placebo subject type 2 diabetes moderate renal impairment .</brief_summary>
	<brief_title>Efficacy Safety Oral Semaglutide Versus Placebo Subjects With Type 2 Diabetes Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age equal 18 year time signing informed consent Diagnosed type 2 diabetes mellitus least 90 day prior day screen HbA1c ( glycosylated haemoglobin ) 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) Moderate renal impairment define estimate glomerular filtration rate 3059 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration formula Stable daily dose ( ) within 90 day prior day screen follow treatment regimen : 12 follow oral antidiabetic drug : Metformin equal 1500 mg maximum tolerate dose document subject medical record ) , Sulfonylurea ( equal half maximum approve dose accord local label maximum tolerate dose document subject medical record ) Basal insulin alone ( 20 % change total daily dose insulin glargine , insulin detemir , insulin degludec NPH insulin ) Metformin ( equal 1500 mg maximum tolerate dose document subject medical record ) combination basal insulin ( 20 % change total daily dose insulin glargine , insulin detemir , insulin degludec NPH insulin ) Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) .For certain specific country : Additional specific requirement apply Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol Family personal history Multiple Endocrine Neoplasia Type 2 Medullary Thyroid Carcinoma History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Any follow : myocardial infarction , stroke hospitalisation unstable angina transient ischaemic attack within past 180 day prior day screen randomisation Subjects presently classify New York Heart Association Class IV Planned coronary , carotid peripheral artery revascularisation know day screen Subjects alanine aminotransferase 2.5 x upper normal limit Rapidly progress renal disease ( e.g . acute glomerulonephritis ) judge investigator know nephrotic albuminuria ( 2200 mg/24 hour 2200 mg/g ) Use systemic immunosuppressive treatment within 90 day prior screen Treatment medication indication diabetes obesity state inclusion criterion period 90 day day screen . An exception shortterm insulin treatment acute illness total equal 14 day Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episode judge investigator Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within 90 day prior randomisation History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer carcinoma situ )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>